These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

253 related items for PubMed ID: 20668448

  • 1. Interpretation and inference in noninferiority randomized controlled trials in drug research.
    Wangge G, Klungel OH, Roes KC, de Boer A, Hoes AW, Knol MJ.
    Clin Pharmacol Ther; 2010 Sep; 88(3):420-3. PubMed ID: 20668448
    [Abstract] [Full Text] [Related]

  • 2. Randomization as a basis for inference in noninferiority trials.
    Wiens BL.
    Pharm Stat; 2006 Sep; 5(4):265-71. PubMed ID: 17128425
    [Abstract] [Full Text] [Related]

  • 3. Making sense of noninferiority: a clinical and statistical perspective on its application to cardiovascular clinical trials.
    Kaul S, Diamond GA.
    Prog Cardiovasc Dis; 2007 Sep; 49(4):284-99. PubMed ID: 17185116
    [Abstract] [Full Text] [Related]

  • 4. Noninferiority drug trials fail to report adequate methodological detail: an assessment of noninferiority trials from 2010 to 2015.
    Hong J, Tung A, Kinkade A, Tejani AM.
    J Clin Epidemiol; 2019 Apr; 108():144-146. PubMed ID: 30529004
    [No Abstract] [Full Text] [Related]

  • 5. An orwellian discourse on the meaning and measurement of noninferiority.
    Diamond GA, Kaul S.
    Am J Cardiol; 2007 Jan 15; 99(2):284-7. PubMed ID: 17223435
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Commentary: The debate on non-inferiority trials: 'when meta-analysis alone is not helpful'.
    Liberati A, D'Amico R.
    Int J Epidemiol; 2010 Dec 15; 39(6):1582-3. PubMed ID: 21113051
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Comparison of dose-finding designs for narrow-therapeutic-index drugs: concentration-controlled vs. dose-controlled trials.
    Lledó-García R, Hennig S, Karlsson MO.
    Clin Pharmacol Ther; 2009 Jul 15; 86(1):62-9. PubMed ID: 19339964
    [Abstract] [Full Text] [Related]

  • 11. Issues with statistical risks for testing methods in noninferiority trial without a placebo ARM.
    Hung HM, Wang SJ, O'Neill R.
    J Biopharm Stat; 2007 Jul 15; 17(2):201-13. PubMed ID: 17365218
    [Abstract] [Full Text] [Related]

  • 12. Superiority trials, noninferiority trials, and prisoners of the 2-sided null hypothesis.
    Sackett DL.
    ACP J Club; 2004 Jul 15; 140(2):A11. PubMed ID: 15122874
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Active-control clinical trials to establish equivalence or noninferiority: methodological and statistical concepts linked to quality.
    Gomberg-Maitland M, Frison L, Halperin JL.
    Am Heart J; 2003 Sep 15; 146(3):398-403. PubMed ID: 12947355
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Choice of comparator in active control trials of new drugs.
    van Luijn JC, van Loenen AC, Gribnau FW, Leufkens HG.
    Ann Pharmacother; 2008 Nov 15; 42(11):1605-12. PubMed ID: 18957629
    [Abstract] [Full Text] [Related]

  • 17. Analysis of clinical data with breached blindness.
    Chow SC, Shao J.
    Stat Med; 2004 Apr 30; 23(8):1185-93. PubMed ID: 15083477
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.